Today: 18 May 2026
Browse Category

SWX:ROG.SW 18 November 2025 - 20 December 2025

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

The MSCI Europe Index closed at 2,564.76 on Dec. 5, down 0.25% after a recent rally, but remains up about 12.5% to 15.5% year-to-date in 2025. The index outpaces the MSCI World, which is up roughly 7.7% for the year. European stocks continue to trade at lower valuations, with a 3.03% dividend yield and forward P/E of 14.64. The MSCI Europe Index has 402 constituents and a market cap near $12.85 trillion.
7 December 2025
···········
Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

The Swiss Market Index closed up 0.07% at 12,781.09 on Wednesday, its highest in about a week, extending a three-day advance. Turnover topped 2.4 million contracts. Investor sentiment jumped after a thaw in Swiss-US trade tensions. Zurich Insurance, Swiss Re, and Swiss Life drew attention after being added to the G20 Financial Stability Board’s insurer resolution list.
26 November 2025
········
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····
Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

The Swiss Market Index fell 0.7% to 12,505 by late morning on November 18, 2025, as global equity declines hit financials and industrials. Roche jumped over 6% to a multi-month high after announcing positive phase III results for its breast cancer drug. ABB, Zurich Insurance, and ams-Osram dropped following investor updates and earnings news. Broader European indices also traded sharply lower.
18 November 2025
····

Stock Market Today

  • Aflac Stock Analysis Highlights Modest Returns and Cautionary Market Signals
    May 17, 2026, 10:11 PM EDT. Aflac's stock returned a modest 0.8% over the past six months, significantly underperforming the S&P 500's 9.9% gain. The insurer's net premiums earned declined at an average annual rate of 6.2% over five years, lagging the insurance sector. Analysts forecast a 2.7% revenue drop in the next year, following two years of flat results, signaling demand challenges. Book value per share is also expected to decrease by 4.8% to $54.37. Trading at twice its forward price-to-book ratio at $115.26 a share, Aflac's valuation suggests positive prospects may already be priced in, prompting recommendations for investors to consider other opportunities.

Latest articles

Rigetti Stock Struggles, Demand for Answers Grows

Rigetti Stock Struggles, Demand for Answers Grows

18 May 2026
Rigetti shares fell 7.37% Friday to $17.85, down about 5.8% for the week, amid heavy trading after earnings. The company reported Q1 revenue of $4.4 million and an operating loss of $26 million. Nasdaq Composite lost 1.5% Friday, while other quantum stocks also declined. CEO Subodh Kulkarni is set to speak at a virtual symposium May 21.
Super Micro Shares Slip, Eyes on Monday for SMCI

Super Micro Shares Slip, Eyes on Monday for SMCI

18 May 2026
Super Micro Computer shares closed at $31.04 Friday, down 6% on the day and 12.2% since May 8, as the Nasdaq fell 1.54%. The company reports $10.24 billion in March-quarter sales, missing analyst estimates and down from $12.7 billion the prior quarter, with a 9.9% gross margin and $6.6 billion in operating cash outflow. Management will address investors Monday at a J.P. Morgan conference.
Exxon to Be Watched Monday After Oil Rally and Court Ruling

Exxon to Be Watched Monday After Oil Rally and Court Ruling

18 May 2026
Exxon Mobil closed Friday at $157.92, up 3.4%, after a surge in crude prices lifted energy stocks. Brent crude settled at $109.26 a barrel and WTI at $105.42, both jumping on concerns over shipping near the Strait of Hormuz. A Texas jury found Exxon not liable in a long-running investor lawsuit. Trading resumes Monday; U.S. markets are closed for the weekend.
Go toTop